Understand the source comparison
Peptide Research News July 2026 Roundup: Clinical Trial Comparison
Nature Neuroscience, July 8 Stanford Medicine Dihexa HGF pathway activation at 0.5 mg/kg protects dopaminergic neurons from oxidative stress Neuroprotection occurs at 40% lower concentration than cognitive enhancement threshold. Expands therapeutic window Cell
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Nature Neuroscience, July 8
- Stanford Medicine
- Dihexa
- HGF pathway activation at 0.5 mg/kg protects dopaminergic neurons from oxidative stress
- Neuroprotection occurs at 40% lower concentration than cognitive enhancement threshold. Expands therapeutic window
- Cell Metabolism, July 15
- Salk Institute
- Survodutide + SLU-PP-332
- Combined therapy increased mitochondrial density 89% vs 22–31% for monotherapy
- Synergistic mitochondrial biogenesis suggests multi-target protocols outperform single-pathway approaches
- Lancet Healthy Longevity, July 22
- National Institute on Aging
- Thymalin
- Restored naive CD4+ T-cells from 17.2% to 31.8% in adults 65–78 over 12 weeks
- First RCT evidence thymic peptides regenerate immune diversity. Not just redistribute existing cells